Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DTIL
stocks logo

DTIL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.08M
+1322.41%
-0.723
-66.14%
2.15M
+7313.79%
-0.820
-62.9%
2.15M
+11844.44%
-0.820
-61.5%
Estimates Revision
The market is revising Upward the revenue expectations for Precision BioSciences, Inc. (DTIL) for FY2025, with the revenue forecasts being adjusted by 25.58% over the past three months. During the same period, the stock price has changed by -0.99%.
Revenue Estimates for FY2025
Revise Upward
up Image
+25.58%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-0.99%
In Past 3 Month
Wall Street analysts forecast DTIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DTIL is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DTIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DTIL is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.020
sliders
Low
30.00
Averages
45.00
High
60.00
Current: 5.020
sliders
Low
30.00
Averages
45.00
High
60.00
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$60
2025-03-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$60
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$60
2025-03-19
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$60
2025-03-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$60
2025-02-19
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$60
2025-02-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$60
2025-01-10
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$60
2025-01-10
Reiterates
Strong Buy
Reason
BMO Capital
Kostas Biliouris
Hold
to
Buy
Upgrades
$34
2025-01-10
Reason
BMO Capital
Kostas Biliouris
Price Target
$34
2025-01-10
Upgrades
Hold
to
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Precision BioSciences Inc (DTIL.O) is -1.58, compared to its 5-year average forward P/E of -2.53. For a more detailed relative valuation and DCF analysis to assess Precision BioSciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.53
Current PE
-1.58
Overvalued PE
1.54
Undervalued PE
-6.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.73
Undervalued EV/EBITDA
-5.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.55
Current PS
0.00
Overvalued PS
13.83
Undervalued PS
-0.73
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DTIL News & Events

Events Timeline

(ET)
2025-11-10
18:20:24
Precision BioSciences Launches $75 Million Common Stock and Warrant Offering
select
2025-11-03 (ET)
2025-11-03
07:08:11
Precision BioSciences Announces Q3 Earnings Per Share of $1.84, Below Consensus Estimate of $2.21
select
2025-10-09 (ET)
2025-10-09
07:19:58
Precision BioSciences Releases Data on ARCUS Nucleases
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

[object Object]
Preview
8.5
11-11SeekingAlpha
Precision BioSciences Initiates $75 Million Stock and Warrant Sale

  • Stock Offering Announcement: Precision BioSciences announced an underwritten offering of approximately 10.8 million shares of common stock, along with warrants for an additional 5.4 million shares, priced at $6.14 per share.

  • Pre-Funded Warrants Details: Certain investors will receive pre-funded warrants for up to 1.4 million shares and half-warrants for 700,000 more shares, priced slightly lower at $6.139995 per unit.

  • Expected Proceeds: The gross proceeds from the offering are anticipated to be around $75 million before deducting underwriting discounts and expenses.

  • Additional Information: The announcement is part of Precision BioSciences' ongoing financial activities, including presentations at investment conferences and historical earnings data.

[object Object]
Preview
8.5
11-11Yahoo Finance
Precision BioSciences Unveils $75 Million Common Stock, Pre-Funded Warrants, and Warrant Offering

  • Offering Details: Precision BioSciences announced an underwritten offering of 10,815,000 shares of common stock and warrants, aiming to raise approximately $75 million for research and development and general corporate purposes.

  • Investor Participation: The offering includes participation from both new and existing investors, such as Aberdeen Investments and Driehaus Capital Management, and is expected to close around November 12, 2025.

  • ARCUS® Platform: Precision BioSciences utilizes its proprietary ARCUS® gene editing platform to develop therapies for diseases with high unmet needs, focusing on delivering lasting cures for genetic and infectious diseases.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding the offering's timing and proceeds, highlighting potential risks and uncertainties that could affect actual results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Precision BioSciences Inc (DTIL) stock price today?

The current price of DTIL is 5.02 USD — it has decreased -0.79 % in the last trading day.

arrow icon

What is Precision BioSciences Inc (DTIL)'s business?

Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

arrow icon

What is the price predicton of DTIL Stock?

Wall Street analysts forecast DTIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DTIL is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Precision BioSciences Inc (DTIL)'s revenue for the last quarter?

Precision BioSciences Inc revenue for the last quarter amounts to 13.00K USD, decreased -97.74 % YoY.

arrow icon

What is Precision BioSciences Inc (DTIL)'s earnings per share (EPS) for the last quarter?

Precision BioSciences Inc. EPS for the last quarter amounts to -1.84 USD, decreased -18.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Precision BioSciences Inc (DTIL)'s fundamentals?

The market is revising Upward the revenue expectations for Precision BioSciences, Inc. (DTIL) for FY2025, with the revenue forecasts being adjusted by 25.58% over the past three months. During the same period, the stock price has changed by -0.99%.
arrow icon

How many employees does Precision BioSciences Inc (DTIL). have?

Precision BioSciences Inc (DTIL) has 108 emplpoyees as of December 05 2025.

arrow icon

What is Precision BioSciences Inc (DTIL) market cap?

Today DTIL has the market capitalization of 120.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free